Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
ERCP (endoscopic retrograde cholangiopancreatography) has been largely demonstrated to be
effective in multiple bilio-pancreatic indications. However, one of the feared complication
of this technique is acute pancreatitis, which happens in 5 to 25% of cases. Some patient
groups have been demonstrated to present a higher risk linked to individual factors or to the
procedure. Some interventions (endoscopic or pharmacologic) have been evaluated to reduce the
incidence of this complication but each has his own inconvenient. Recently, the activation of
heme oxygenase (HO) by intraperitoneal administration of hemin has been demonstrated to be
effective in prevention and treatment of acute pancreatitis mice models. This protective
effect has been associated to intrapancreatic HO-1 positive macrophage recruitment activated
by hemin. The investigators thus propose to conduct a prospective randomized double blind
controlled trial to demonstrate a protective effect of hemin administration against post-ERCP
acute pancreatitis in high risk patients.